Global Diabetes Drugs Market Set To Grow To $66bn By 2021

14 August 2018
Pharma

Visiongain’ has launched a new pharma report Global Diabetes Drugs Market 2017-2027:
Insulin and Insulin Analogues, DPP-4 Inhibitors, Biguanides, GLP-1 Agonists, Alpha-glucosidases, SGLT-2 Inhibitors, Sulfonylureas and Others

The IDF (International Diabetes Federation) predicts that by 2035, the global number of diabetics will reach over 582 million. While the market associated with type 1 diabetes will grow in line with population rate, the type 2 diabetes market will expand much more rapidly due to the aging of the general population, poor dietary habits and sedentary lifestyles, the latter two of which can be attributed to a growing urbanised and westernised population.

As with most disease medications, the diabetes drug industry is prone to generic competition. Despite this, the market still attracts new interest from drug firms, giving rise to an influx of new diabetes therapies. Continued research in this area will either lead to the development of a drug that is a slight modification on a current existing class of diabetes drug, or will uncover a new molecular target entirely. Most of the drugs currently in development are modifications and improvements to existing therapies, such as longer-acting insulins and new DPP-4 inhibitors.

The lead analyst of the report commented “Owing to the growing incidence of diabetes worldwide, especially in the Middle East, the Western Pacific region and Asia, there continues to be a tremendous need for newer anti-diabetic treatments with improved efficacy and safety, which translates to significant opportunities for drug manufacturers operating in this potentially lucrative market.

Moreover, as obesity is closely related to type 2 diabetes, medications that target long-term weight reduction and those that treat co-morbid conditions, are in demand. Consequently, many researchers are currently focused on developing diabetes therapies that can tackle multiple complications that follow the disease, particularly obesity and heart-related illnesses.”

Leading companies featured in the report include Novo Nordisk, Sanofi, Merck (MSD), Eli Lilly
Boehringer Ingelheim, Novartis, AstraZeneca, Takeda and other leading companies currently marketing or developing diabetes drugs.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Generic Drugs market set to grow to $424bn by 2024” says new Visiongain report

Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.

14 June 2019

Read

“Global Precision Cancer Diagnostic Tests market set to grow to $21.3bn by 2024” says new Visiongain report

The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.

06 June 2019

Read

“Global Antifungal Drugs market set to grow to $17bn by 2024” says new Visiongain report

Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.

04 June 2019

Read

“Global Ophthalmic Equipment market set to grow to $75bn by 2024” says new Visiongain report

here is a growing demand for ophthalmic equipment such as vision care products and ophthalmology surgical devices, mainly due to the increasing incidence of myopia across the world.

03 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever